Attendees are accustomed to hearing results from phase III trials of investigational agents at the annual meeting of the American Society of Clinical Oncology (ASCO). And at the 2016 meeting, which ran from June 3-7, there were some of those presentations. But the denizens of McCormick Place found themselves contending with somewhat atypical fare this year, with less than the usual buzz around such trials.